Skip to Main Content Skip to Site Map Skip to Accessibility Statement

PROMISE

September 7, 2022
Trial PROMISE
Cancer Type Haematological Cancers and Other Haematological
Hospital(s) Belfast City Hospital
Information

Investigation Into The Combination Of PLX2853 With Ruxolitinib In Patients With Intermediate-2 Or High Risk Myelofibrosis Not Receiving An Adequate Response With Ruxolitinib Alone